Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) FCF Margin (2016 - 2025)

Historic FCF Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 17.91%.

  • Anika Therapeutics' FCF Margin rose 50600.0% to 17.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 15100.0%. This contributed to the annual value of 1.94% for FY2024, which is 40300.0% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' FCF Margin is 17.91%, which was up 50600.0% from 5.87% recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' FCF Margin peaked at 73.48% during Q4 2022, and registered a low of 62.02% during Q4 2023.
  • For the 5-year period, Anika Therapeutics' FCF Margin averaged around 0.62%, with its median value being 0.9% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first soared by 641500bps in 2022, then plummeted by -1355100bps in 2023.
  • Anika Therapeutics' FCF Margin (Quarter) stood at 9.34% in 2021, then skyrocketed by 687bps to 73.48% in 2022, then tumbled by -184bps to 62.02% in 2023, then skyrocketed by 101bps to 0.9% in 2024, then skyrocketed by 1893bps to 17.91% in 2025.
  • Its last three reported values are 17.91% in Q3 2025, 5.87% for Q2 2025, and 11.29% during Q1 2025.